Related Experiment Video
Updated: Apr 23, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Current concepts on the molecular pathology of non-small cell lung carcinoma
Junya Fujimoto1, Ignacio I Wistuba2
1Department of Translational Molecular Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Abstract:
Recent advances in the understanding of the complex biology of non-small cell lung carcinoma (NSCLC), particularly activation of oncogenes by mutation, translocation and amplification, have provided new treatment targets for this disease, and allowed the identification of subsets of NSCLC tumors, mostly with adenocarcinoma histology, having unique molecular profiles that can predict response to targeted therapy. The identification of specific genetic and molecular targetable abnormalities using tumor tissue and cytology specimens followed by the administration of a specific inhibitor to the target, are the basis of personalized lung cancer treatment. In this new paradigm, the role of a precise pathology diagnosis of lung cancer and the proper handling of tissue and cytology samples for molecular testing is becoming increasingly important. These changes have posed multiple new challenges for pathologists to adequately integrate routine histopathology analysis and molecular testing into the clinical pathology practice for tumor diagnosis and subsequent selection of the most appropriate therapy.
Insights
Advances in non-small cell lung carcinoma (NSCLC) biology reveal molecular targets for personalized therapy. Precise pathology and molecular testing are crucial for selecting effective treatments in this new era of precision oncology.
Area of Science:
- Oncology
- Molecular Biology
- Pathology
Background:
- Non-small cell lung carcinoma (NSCLC) biology is complex, with oncogene activation driving disease progression.
- Recent discoveries have identified specific molecular targets, particularly in adenocarcinoma subtypes.
- These targets enable the development of targeted therapies, forming the basis of personalized lung cancer treatment.
Purpose of the Study:
- To highlight the importance of precise pathology diagnosis in the era of targeted NSCLC therapy.
- To emphasize the critical role of molecular testing in identifying actionable mutations.
- To discuss the challenges pathologists face in integrating molecular diagnostics into clinical practice.
Main Methods:
- Identification of genetic and molecular abnormalities in NSCLC using tumor tissue and cytology specimens.
- Administration of targeted inhibitors based on identified molecular profiles.
- Integration of routine histopathology with advanced molecular testing.
Main Results:
- Specific molecular profiles in NSCLC subsets predict response to targeted therapies.
- Personalized treatment strategies are increasingly reliant on molecular diagnostics.
- Pathology practices are evolving to incorporate comprehensive molecular profiling.
Conclusions:
- Precise pathology and molecular testing are essential for effective NSCLC treatment selection.
- The integration of histopathology and molecular diagnostics presents new challenges for pathologists.
- This paradigm shift enhances the potential for improved patient outcomes through personalized medicine.
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:39lncRNA - Long Non-coding RNAs